Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$113.18 USD
+0.89 (0.79%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $113.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Fundamental Charts
About Market Cap
As of the previous market close, Gilead Sciences, Inc. has a market cap of $139.68B, which represents its share price of $112.29 multiplied by its outstanding shares number of 1.24B. As a large-cap company, GILD's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
GILD 113.18 +0.89(0.79%)
Will GILD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GILD
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
Top Research Reports for NVIDIA, Netflix & Goldman Sachs
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
Other News for GILD
Earnings Scorecard: 18 out of 21 healthcare firms beat earnings forecast this week
Notable healthcare headlines for the week: Trump’s ultimatum to big pharma, Novo Nordisk, UnitedHealth and Moderna in focus
Earnings week ahead: AMD, PLTR, PFE, DIS, O, ET, SHOP, GILD, MCD, CAT, VTRS, BP, UBER, CGC, and more
ClearBridge Value Portfolios Q2 2025 Commentary
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality